🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Compared to Goteborg 2 screening (PSA then MRI; NEJM) and PROSCREEN (PSA then marker then MRI; JAMA), BARCODE PRS based screening found fewer significant cancers (grade group 2+), more insignificant cancer and biopsied more men (the trifecta!). nejm.org/doi/full/10.10…

We have a fully funded 3 year PhD post UCL starting Aug 2025. Research is on optimising prostate cancer diagnosis using imaging (e.g MRI, PET, AI). Join our world-class team with proven track-record for changing practice. DM me if interested BURST Urology The British Society of Urogenital Radiology European Society of Residents in Urology

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials ascopubs.org/doi/abs/10.120… This study validates a novel

"Expanding eligibility for AS and the uptake of AS in men with favourable GG2 PCa is crucial to address the stage shift resulting from the increased accuracy of MRI." bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

New #JITC hypothesis: Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancer bit.ly/42pfzYF

#AUA25 kicks straight off with a thorny topic: do we really understand localised prostate cancer? Answer: clearly no! We can't even agree on our age-old risk strat criteria: •GG1, PSA 21, 150cc = High risk 🤔 •GG2 49% ≠ GG3 51% 😂 •GG4 2mm 100% 4 worse than GG2 12mm 40% 4🤦

La supériorité du sasanlimab + BCG vs BCG seul dans les TVNIM représente un tournant pour les urologues dans la prise en charge du cancer de vessie: il s’agit d’une immunothérapie à domicile par voie sous cutanée. En espérant rapidement AMM et remboursement . Association Française d'Urologie - AFU

Crossfire: Controversies in #Urology: intermediate-risk #ProstateCancer: is #FocalTherapy a suitable option for all cases? Presentation by Samir Taneja, Edward Schaeffer, MD, PhD, Lara Rodríguez Sánchez, Hashim U. Ahmed, and Himanshu Nagar. #AUA25 written coverage by Julian Chavarriaga University of Toronto >

Pattern 4 quantification is superior to biopsy Grade group for prediction of recurrence and metastases in #prostatecancer Andrew Vickers #aua25

Day 2 at #AUA25! The work on preoperative pattern 4 quantification and metastatic recurrence prediction, from the CHU de Lille Urology Team led by Jonathan Olivier, is now being presented by Andrew Vickers.

In further #RAPID data, Chase Ng shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without #AUA25 Alexander Light

I have seen multiple papers on the prognostic impact of % pattern 4 on outcomes of treated patients (MSKCC, U of M, and other pubs). What is the best study showing this for AS patients?

Daniel E Spratt Dave Penson There is this pubmed.ncbi.nlm.nih.gov/40034920/. I'm not aware of any paper looking at risk of upgrading by amount of 4 in patients with GG2 on AS but would argue that is an odd study: we want to replace GG by pattern 4 quantification, so GG not the right endpoint.

Game-changer in prostate cancer risk stratification! PSMA-PET isn’t just for staging—it predicts survival. European Urology Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU) Prostate Cancer Foundation Ken Herrmann Michael Hofman doi.org/10.1016/j.euru…

See our latest ARCHES analysis showing PSA nadir long term survival outcomes. ENZA/ADT durably beneficial even in those w/low PSA levels on initial ADT JAMA Network Open Arun Azad jamanetwork.com/journals/jaman… Duke Cancer DCI Center for Prostate & Urologic Cancers

Le programme de la Journée Scientifique 2025 de l'#ARTP est disponible : iartp.org “Insights into Nuclear Receptors, Epigenetics, and Transcriptomics Landscapes of prostate cancer” Carmen Jeronimo (Abel Salazar Biomedical Sciences Institute, Porto, Portugal)

Original Article: Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial by Guillaume Ploussard et al Read the full article here: buff.ly/7oFX5W4 Come back later for the

🚨 PUBLICATION ALERT Our 🔥 hot-off the press 🔥 systematic review + meta-analysis (63 studies, >4000 patients) 📜 in Eur Urol Focus European Urology with new insights into ULTRASOUND 🔎for suspected #testiculartorsion 👨‍🦱 Read full paper 👉 authors.elsevier.com/a/1l5Fs_siPeZS… #UroSoMe

What is the best evidence that presence of cribriform improves our ability to risk stratify prostate cancer? Please send citations to papers showing e.g. improvement in discrimination of a standard nomogram.

📢Publication alert! Highlights: 1⃣Across 11 trials, TMT was associated with lower OS and CSS than RC 2⃣RC should remain the standard of care for nonmetastatic MIBC 3⃣TMT remains a valid alternative for carefully selected and informed patients 🔗bit.ly/4e4KayS